Overview of Emetiral

Property	Description
Active ingredient	Prochlorperazine
Form	Tablet, Suppository, Injectable solution
Pharmacological class	Antiemetic, First-Generation Antipsychotic
Common use	Relief of severe nausea and vomiting
Origin	Synthetic, Phenothiazine derivative

What Type of Medicine is Emetiral (Prochlorperazine)?

Emetiral is a brand name for the prescription-only pharmaceutical agent containing the active ingredient Prochlorperazine. It is chemically defined as a phenothiazine derivative, a type of synthetic compound. Pharmacologically, Prochlorperazine is classified as a potent antiemetic agent, and it belongs to the class of first-generation (typical) antipsychotics.

This medication is supported by pharmacological studies and is utilized globally, with other brands containing this same formulation including Compazine and Stemetil. While its foundational classification is an antipsychotic, its dominant use and positioning are as an antiemetic, reflecting its high reliability in managing acute physical distress.

Composition and Available Dosage Forms

Emetiral is a single-component product whose therapeutic effect is derived entirely from the Prochlorperazine molecule, typically stabilized as the Maleate or Edisylate salt. A key feature of Prochlorperazine is its wide array of delivery methods: it is available as standard oral tablets and capsules, as well as rectal suppositories. For rapid or compromised oral administration, it is also prepared as a sterile injectable solution for parenteral delivery.

The availability of multiple forms ensures that the antiemetic agent can be administered effectively, even in acute situations where the patient cannot keep oral medication down, making the injectable and suppository options important factors that differentiate its use from typical over-the-counter anti-nausea preparations.

The General Purpose of This Phenothiazine Antiemetic

The core purpose of this medication is to reliably relieve severe nausea and vomiting by inhibiting the neurological signals that trigger the reflex. Prochlorperazine achieves this by blocking dopamine D2 receptors in the brain's chemoreceptor trigger zone (CTZ), the area responsible for initiating the vomiting response. This targeted, central mechanism ensures that Emetiral can effectively suppress the reflex originating from chemical imbalances, serving the general purpose of stabilizing the patient and providing effective relief in acute scenarios like post-operative nausea.

Regulatory References

Prochlorperazine

What side effects are possible with Emetiral?

Possible Side Effects and Safety Information

The safety profile of Emetiral (Prochlorperazine) is officially characterized by a range of adverse reactions, primarily reflecting its activity as a phenothiazine derivative. The documented effects are classified across several system-organ classes.

Officially Classified Adverse Reactions and Systems

System-Organ Class	Key Adverse Reactions	Frequency Notes
Nervous System	Extrapyramidal Symptoms (EPS), Drowsiness, Dizziness, Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD), Convulsions.	NMS, TD, and EPS are documented risks. Drowsiness is noted especially during the first few days of therapy.
Cardiovascular	Hypotension, QT prolongation, Cardiac Arrhythmias (e.g., ventricular fibrillation, cardiac arrest).	Frequency often classified as Not Known.
Blood/Endocrine	Blood Dyscrasias (e.g., agranulocytosis), Hyperprolactinaemia.	Blood Dyscrasias are Rare; Hyperprolactinaemia is Very Rare.

Serious adverse reactions listed in regulatory documents include the potentially irreversible Tardive Dyskinesia and the rare, serious Neuroleptic Malignant Syndrome (NMS). There is also an official warning concerning increased mortality when antipsychotics are used in elderly patients with dementia-related psychosis, an unapproved use.

Population and Exposure Constraints

Specific safety considerations exist for certain groups. The drug is generally not recommended for children under 2 years of age or weighing less than 20 pounds. Neonates exposed during the third trimester of pregnancy are at risk for withdrawal or extrapyramidal symptoms after delivery. Furthermore, the risk of Tardive Dyskinesia is noted to increase with the duration of treatment and cumulative exposure. The drug's antiemetic effect can mask the signs of other underlying conditions, such as intestinal obstruction or brain tumors, a limitation documented in the official labeling.

Overdose and Emergency Response

Emetiral Overdose and When to Seek Help

Overdose with Emetiral (prochlorperazine) is officially documented to involve acute effects on the Central Nervous System and cardiovascular function. Manifestations may include severe symptoms such as coma, convulsions (seizures), and profound drowsiness or disorientation. Neuromuscular signs, known as Extrapyramidal Symptoms (EPS), like muscle spasms and involuntary facial movements, are also recognized presentations.

Life-threatening outcomes include severe low blood pressure (hypotension) and potentially fatal cardiac rhythm disturbances. A potentially fatal symptom complex, Neuroleptic Malignant Syndrome (NMS), is listed in the drug's official profile.

Immediate Emergency Action Required

Regulators mandate that individuals must seek immediate medical attention and contact a poison control center or emergency room at once if an overdose is suspected. Since no specific antidote is known, treatment is strictly symptomatic and supportive. Supportive measures described in official labeling include the use of activated charcoal, fluid administration, and specific management protocols for hypotension and EPS.

Furthermore, continuous monitoring via ECG and diagnostic testing are typically required. Special consideration is noted for elderly patients with dementia-related psychosis due to an increased mortality risk.

Therapeutic Uses of Emetiral

Emetiral (prochlorperazine) is a prescription antiemetic commonly used to provide supportive symptomatic relief in conditions marked by severe and distressing manifestations. It helps address groups of symptoms that may appear suddenly or intensify over time, applied during phases when symptoms become more noticeable and interfere with daily comfort.

Applied for Symptom Clusters of Severe and Intractable Nausea and Vomiting

This medication is commonly used in clinical settings marked by heightened patient distress to manage severe nausea and intractable vomiting—symptoms that are intense and disruptive. Its use is relevant when short-term, symptomatic assistance is needed to support general well-being during symptomatic phases, thereby contributing to easing the overall symptom load during acute emesis.

Supportive Relief in Acute Clinical Contexts

Emetiral is also applied across domains where additional symptomatic support is needed for conditions that present with disruptive symptom manifestations in specific medical contexts. This includes managing the cluster of vertigo, dizziness, and associated sickness related to labyrinthine disorders, such as Ménière's disease. It is also relevant during phases of heightened discomfort, such as postoperative nausea and vomiting (PONV) or the intense sickness that frequently accompanies severe migraine headaches.

Quick Fact: Relief for Severe Sickness

Emetiral is commonly used for symptoms that create noticeable physiological strain, including intense sickness, vomiting, and inner-ear related dizziness, especially when supportive symptom management is appropriate in acute settings.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Emetiral (Prochlorperazine) eligibility is strictly defined by regulatory documentation to ensure appropriate use. The medicine is generally permitted for Adults and for Children 2 years of age and older weighing at least 9 kg (20 lbs), provided no contraindications are present.

Contraindicated Populations

Use is absolutely prohibited in patients with known phenothiazine hypersensitivity, blood dyscrasias, circulatory collapse, or those in a comatose state. It is also contraindicated in older adults for dementia-related psychosis and in children undergoing surgery.

Restricted and Conditional Use

Eligibility is limited for several groups. Use is not recommended in children under 2 years of age or the specified minimum weight. It is not recommended during the third trimester of pregnancy due to risk to the neonate, and caution is required during breastfeeding. Furthermore, patients with severe hepatic impairment, renal insufficiency, Parkinson's disease, or narrow-angle glaucoma must use the medication with caution or avoid it entirely, as defined in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Emetiral (Prochlorperazine) through specific restrictions and documented pharmacokinetic and pharmacodynamic constraints. These statements strictly reflect information published in government drug labeling.

Contraindicated Combinations and Enhanced Pharmacodynamic Effects

Co-administration with medicines known to significantly prolong the QT interval is restricted, as regulatory bodies identify a risk of serious ventricular arrhythmias. This includes agents such as Pimozide, Sotalol, and Dofetilide. Furthermore, Prochlorperazine exhibits pharmacodynamic potentiation with other Central Nervous System (CNS) depressants, including alcohol, general anesthetics, and narcotics, which may intensify or prolong the action of these substances. Concomitant use with Lithium is documented to increase the risk of severe extrapyramidal effects or neurotoxicity. The medicine may also exaggerate the hypotensive effect of co-administered antihypertensive drugs, and due to a potential to lower the seizure threshold, it may diminish the efficacy of anticonvulsants.

Pharmacokinetic and Timing Restrictions

Regulatory information specifies that food slows the absorption of the oral formulation, resulting in a formal decrease in the maximum concentration ( C max) and total exposure ( AUC). A strict timing rule exists regarding the radiological contrast agent Metrizamide, requiring Prochlorperazine to be discontinued 24 hours prior to administration. Official labeling also notes that the risk of the cardiac arrhythmia interaction is predisposed by the presence of uncorrected electrolyte imbalances, such as hypokalemia or hypomagnesemia.

Mechanism of Action

Central Suppression of the Vomiting Reflex

The primary mechanism of Prochlorperazine is the antagonism (blocking) of dopamine D2 receptors (D2 Receptors) within the Chemoreceptor Trigger Zone (CTZ). By blocking these receptors, the molecule prevents circulating emetic substances from stimulating the CTZ, which is the key area that signals the Vomiting Center to initiate the reflex. This molecular cascade suppresses the entire reflex pathway, resulting in the inhibition of the physiological emesis response.

Non-Selective Neurotransmitter Modulation

As a phenothiazine derivative, the molecule also engages in non-selective antagonism across several other central and autonomic targets, including Histamine H1 receptors, Muscarinic Cholinergic receptors (M-receptors), and Alpha-1 Adrenergic receptors (alpha1). This broad modulation influences general neural excitability, contributing to overall CNS dampening and affecting autonomic function, which further defines the molecule's spectrum of pharmacological activity.

Dosage and Administration Information

Emetiral (prochlorperazine) is administered via multiple official routes, allowing for necessary flexibility in clinical use. The approved delivery methods include oral intake (tablet/capsule), rectal suppository insertion, and parenteral delivery via intramuscular (IM) or slow intravenous (IV) injection.

Instruction	Detail (Official Administration Guidelines)
Route of Administration	Approved for Oral, Rectal, Intramuscular, Intravenous, and Buccal administration. The Subcutaneous route is not advised.
Dosing Schedule & Frequency	For severe nausea and vomiting in adults, oral doses are typically 5 to 10 mg taken 3 to 4 times daily, not to exceed 40 mg per day. For anxiety, the maximum duration is 12 weeks, with a daily oral limit of 20 mg.
Age-Group Rules	Use is strictly not recommended in children under 2 years of age or under 9 kg (20 lbs). In older adults, a cautious approach with a lower initial dosage is generally recommended.
Special Procedural Conditions	Intravenous administration must be given as a slow injection, with the rate not exceeding 5 mg per minute, and bolus injection must be avoided. The IM route requires a deep injection into the upper, outer quadrant of the buttock.

This procedural framework defines the required structure for administering the medicine, detailing the permitted routes of entry into the body and the precise maximum quantities allowed over a 24-hour period. These constraints standardize parenteral delivery by mandating slow IV injection rates and specific IM locations, ensuring proper technique is followed and defining the necessary boundaries of official, label-compliant use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Emetiral

Research Evidence for Acute Severe Nausea and Vomiting

The research base includes Randomized Controlled Trials (RCTs) and Systematic Reviews conducted in acute care settings. This evidence was studied for Emetiral, the brand name for prochlorperazine, in adults experiencing sudden and intense sickness. Studies examined patients with conditions like gastroenteritis, where symptoms become more noticeable. Researchers monitored patient-reported outcomes describing perceived discomfort, such as the degree of change in nausea severity scores, and the time it took for the vomiting to cease.

While the evidence for short-term use in generally healthy adults has been extensively studied, follow-up durations were limited. Research provides context but not individual predictions for patients with complex medical backgrounds.

Research for Migraine-Associated Nausea and Headache Relief

Emetiral was evaluated in studies exploring its role in managing acute migraine attacks. The research includes RCTs and Meta-analyses which examined outcomes related to both headache pain and the severe, associated nausea and vomiting. Research has examined whether the administration of Emetiral was associated with changes in migraine headache pain. Findings describe patterns observed in the studies related to the proportion of patients who reported a reduction in their overall discomfort within the first few hours.

Evidence for Preventing and Treating Postoperative Sickness (PONV)

Research explored the role of Emetiral in both the prevention and treatment of nausea and vomiting following surgical procedures (PONV). Study populations were adults undergoing various surgical procedures who were monitored for outcomes capturing phases of heightened symptom activity immediately following anesthesia.

Gaps in the Research and Areas of Uncertainty

The body of research highlights what is known — and what is still uncertain. There is limited information for long-term outcomes for any indication, meaning evidence for using the medicine beyond the acute phase is sparse. Comparative evidence is limited when Emetiral's use is examined against other classes of antiemetics. Subgroup findings are uncertain when trying to apply the research to patients with multiple, complex health conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Emetiral (FAQ)

Q: Is Emetiral the same type of medicine as other common treatments for the same condition?

Official documents classify Emetiral as a phenothiazine derivative, which is a type of synthetic compound. Its primary action involves working as a potent dopamine D2 receptor antagonist. This specific way of working on D2 receptors is what sets it apart from many other antiemetics that may work through different chemical pathways, such as those that target serotonin or histamine receptors.

Q: What is the difference between Emetiral and a standard over-the-counter nausea remedy?

Emetiral is a prescription-only medication, meaning it requires authorization from a healthcare professional. According to official product information, it is approved for the treatment of severe nausea and vomiting. Unlike standard over-the-counter remedies, its chemical structure is classified as a phenothiazine derivative, and it works centrally by blocking dopamine receptors.

Q: Do people usually take Emetiral daily or only as needed?

The official dosing information describes schedules for both acute, short-term use for severe nausea and vomiting (which has an approved frequency schedule) and for longer-term use for other conditions. For example, use for anxiety has a specific maximum duration of 12 weeks. The prescribed schedule depends entirely on the condition being addressed.

Q: What kind of side effects are most frequently reported for Emetiral?

Regulatory documents describe Drowsiness as a common reaction that is frequently reported, especially during the first few days of therapy. Other documented effects include dizziness and symptoms related to the nervous system. The official safety information contains a detailed list of all possible adverse reactions.

Q: Are there any specific foods or drinks that should be avoided when using Emetiral?

Official documents advise that alcohol may intensify the effects of the medicine and is documented to require caution in official product information. The documents also note that taking the oral formulation with food slows the body's ability to absorb the medicine, which leads to a reduction in the maximum concentration (Cmax) in the blood.

Q: How quickly does Emetiral typically start working after it is taken?

According to regulatory labeling, the onset of action for the oral tablet is generally described as occurring within approximately 30 to 40 minutes following ingestion. The time it takes to notice an effect may vary based on the method of administration.

Q: Is Emetiral described as safe for people over 65 years of age?

Official guidance notes that a lower initial dosage is generally recommended for older adults. Furthermore, the medicine is contraindicated (prohibited) for use in elderly patients with dementia-related psychosis.

Q: Is Emetiral a first-line treatment, or is it reserved for certain situations?

The medicine's primary approved use, as defined in its official indications, is for the treatment of severe nausea and vomiting. This context in the indications section describes its use in situations where symptoms are severe. It is also approved for the short-term management of certain anxiety states.

Q: Does Emetiral carry any warnings about driving or operating machinery?

Yes, official warnings describe a risk of impaired mental or physical abilities required for performing hazardous tasks such as operating machinery or driving a motor vehicle. This warning is included primarily because of the potential for the medicine to cause drowsiness or dizziness.

Q: Why do official documents mention warnings about rare, serious conditions like NMS (Neuroleptic Malignant Syndrome) for Emetiral?

Emetiral is chemically classified as a first-generation antipsychotic (phenothiazine derivative). Regulatory bodies require that warnings for rare, serious conditions like Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD) be included as a standard regulatory requirement for all medicines within this therapeutic class.

Q: Can Emetiral affect sleep patterns?

Official drug documents report drowsiness as a common side effect of the medicine, especially during the first few days of use. This effect is related to the medicine's overall Central Nervous System (CNS) dampening activity, which may affect the patient's state of alertness.

Q: What is the general safety classification of Emetiral from regulatory bodies?

Regulatory documents include serious warnings, such as the risk of increased mortality when used off-label in elderly patients with dementia-related psychosis, and warnings regarding potentially irreversible Tardive Dyskinesia.

Q: Is Emetiral available over the counter in some countries?

Regulatory databases across major governmental jurisdictions show that Emetiral (Prochlorperazine) is generally classified as a prescription-only medicine (POM). This indicates that a prescription from a licensed professional is typically required for its use.

Q: What is the difference between Emetiral and other 'antiemetic' drugs?

Official sources describe Emetiral's mechanism as working primarily through the blockade of dopamine D2 receptors in the brain’s chemoreceptor trigger zone. This specific approach to neurological signaling is the main pharmacological difference between Emetiral and antiemetics that act on other pathways.

Q: Are there specific symptoms that warrant immediate medical attention while using Emetiral?

Regulatory documents specifically list certain serious adverse reactions that require prompt medical attention. These may include signs of Neuroleptic Malignant Syndrome (NMS), which involves fever and muscle rigidity, or symptoms of severe circulatory collapse (very low blood pressure) and life-threatening heart arrhythmias.

Q: Why is Emetiral contraindicated for people with specific types of glaucoma?

The medicine is classified as having anticholinergic properties, which means it may affect nerve signaling in ways that influence specific bodily systems. Due to this property, official regulatory documents advise caution or contraindication for use in patients with narrow-angle glaucoma.

Q: Is it possible to take Emetiral if I am already taking an antidepressant?

Regulatory documents warn against taking Emetiral with other medicines that are known to significantly prolong the QT interval or are classified as Central Nervous System (CNS) depressants. These combinations may intensify effects or pose specific cardiac risks. The full list of documented interactions is available in the official product information.

Q: Is it normal to feel dizzy after taking Emetiral?

The adverse reaction profile officially lists Dizziness as a documented and commonly reported effect of the medicine. This reaction is documented as a commonly reported effect of the medicine.

Q: What is the recommended period of time to wait between taking Emetiral and other medications?

Official drug labeling includes a specific timing restriction requiring the medicine to be discontinued 24 hours prior to the administration of the radiological contrast agent Metrizamide. No general waiting period for other medications is specified in the regulatory documents.

Q: Is Emetiral considered a controlled substance?

In the United States, regulatory classification systems, such as those used by the Drug Enforcement Administration (DEA), do not classify this medication as a controlled substance.

Q: How long does the effect of Emetiral usually last?

Following a typical dose, the antiemetic effect is documented in regulatory sources as typically lasting for approximately 3 to 4 hours. Official documentation notes a typical duration, but individual experiences may vary based on metabolism and other factors.

Q: Does taking Emetiral make people feel 'spaced out' or anxious?

Official sources report symptoms such as drowsiness and dizziness, which may contribute to generalized changes in perception or mood. However, regulatory documents do not use the specific colloquial phrase 'spaced out' when describing the recognized side effects.

How should Emetiral be stored and disposed of?

Emetiral (prochlorperazine) must be stored strictly according to the conditions documented in regulatory labeling to maintain its stability and effectiveness.

Storage Requirement	Official Condition (Tablets)
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection	Protect from heat, moisture, and direct light; do not freeze
Container	Keep in the original, tightly closed, light-resistant container
Child Safety	Must be stored out of the reach of children

For disposal, regulatory agencies recommend returning unused or expired Emetiral to a drug take-back program. If no program is available, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed container, and then discarded in the household trash. All personal information on the prescription label must be removed or scratched out prior to discarding the packaging.

Emetiral